Neutral
●
Proactive Investors
●
about 2 months ago
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO), arguing that the market's reaction to a failed heart drug trial looks somewhat overdone while flagging deeper concerns about pricing and competition in obesity. The Danish group announced that ziltevekimab, an anti-inflammatory antibody targeting the protein interleukin-6, missed the primary endpoint of its ZEUS trial.